The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Reading a supplementary appendix and finding the interesting part

This is a generated summary. It shows the 9 most-liked posts from a topic of 93, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
PK
p.krastevTL229 Sep 2024#1

Reading a supplementary appendix and finding the interesting part — setting out what I have, and where I think it stops being reliable.

Collecting what is known about reading a supplementary appendix in one place, because it is currently spread across a category, two tag pages and a thread that is hard to find.

This is a summary rather than new work, and I have attributed each part to where I found it.

52 likes 22mo
SA
s.adebayoTL231 Oct 2024 · edited#15

Two claims get bundled together under reading a supplementary appendix and they need separating. The descriptive one — this is what was observed — is usually well supported. The causal one — this is why — usually is not.

Almost every disagreement in threads like this one dissolves once you say which of the two you are making.

32 likes 21mo
GH
g.haalandTL3Regular2 Dec 2024#35

The arithmetic in post #34 is right; the assumption feeding it is the part to check.

Risk of bias: structured appraisal of internal validity. Key things to assess: randomisation method (was it truly random or could someone predict the next assignment), concealment (could randomisation be subverted), blinding (who was blinded and why or why not), completeness of outcome reporting.

Worth one more sentence than it usually gets.

27 likes 20mo
BV
bias_varianceTL4Biostatistician10 Dec 2024#41

A treatment-policy estimand asks what happens to people assigned to a strategy, including those who abandon it. A hypothetical estimand asks what would have happened had everyone continued. Both are legitimate and they give different numbers.

28 likes 20mo
SK
s.karlsen_rphTL3Pharmacist8 Jan 2025#62

Adding the measurement that post #59 says would settle it.

Worth stating the null on reading a supplementary appendix before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.

31 likes 19mo
CC
c.correiaTL216 Jan 2025 · edited#69

Something worth flagging about reading a supplementary appendix: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and not a coincidence.

32 likes 18mo
AS
a.stephanopoulosTL3Regular24 Jan 2025#75

A treatment-policy estimand asks what happens to people assigned to a strategy, including those who abandon it. A hypothetical estimand asks what would have happened had everyone continued. Both are legitimate and they give different numbers.

That is the practical version. The rigorous version is longer and says the same thing.

28 likes 18mo
VD
vial_deskTL3Regular6 Feb 2025#86

Discontinuation handling is the methodological detail that most changes a result and gets the least attention. Read how missing data was imputed before reading the effect size.

The reasoning is more useful than the number, which is why I have shown it.

26 likes 18mo
KO
k.otieno_statsTL3Statistician13 Feb 2025#92
d.achebe, post #19: Reading a supplementary appendix has been discussed here with more heat than it deserves, mostly because two definitions have been in play the whole time. Go to post

I read post #90 twice before replying, because I had assumed the opposite.

I changed my mind about reading a supplementary appendix after someone here asked me for the source and I could not produce one. That is worth saying out loud because it is the ordinary way it happens.

28 likes in reply to #19 17mo

Read the full topic (93 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
About the Trials category
Individual randomised trials: design, population, endpoints, results, and limitations. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…
JMBNSSZOEM+6 10 27k 12mo
[2026 update] Reading a supplementary appendix and finding the interesting part
On the subject in the title: Reading a supplementary appendix and finding the interesting part Working notes rather than a conclusion. Collecting what is known about Reading a supplementary appendix in one…
KFIDFIOCH+39 44 8.2k 5mo
[2026 update] How to read a forest plot, properly, from scratch
How to read a forest plot, properly, from scratch — that is the question, and I have not found it answered plainly anywhere I have looked. Reading SURMOUNT-4 ( JAMA , 2024) for the population rather than the…
AZVNLWFKK+49 53 643 19mo
How to read a forest plot, properly, from scratch
The question in the title: How to read a forest plot, properly, from scratch I will give what I have already checked below so nobody repeats it. Reading STEP 4 ( JAMA , 2021) for the population rather than…
SCPDBJRMYM+73 81 17k 7mo
Primary endpoint hierarchies and why order matters — one year on
On the subject in the title: Primary endpoint hierarchies and why order matters — one year on Working notes rather than a conclusion. A follow-up question about Primary endpoint hierarchies that I did not…
SCAJNGRMGT+56 61 37k 11h

Related topics — sharing the tags open label, discontinuation & dropout, intention to treat

TopicParticipantsRepliesViewsActivity
Journal club: STEP 8 and the fairness of the comparator dose
Journal club: STEP 8 and the fairness of the comparator dose — setting out what I have, and where I think it stops being reliable. Session topic: STEP 8 ( JAMA , 2022). Please read it before posting; the…
ANBRCCDSO+2 6 39k 12mo
The CagriSema phase 2 paper and what a fixed combination buys
Posting this under the heading it deserves: The CagriSema phase 2 paper and what a fixed combination buys Everything below is what sits behind that. Working notes on cagrisema phase 2 paper rather than a…
DSTDEFRECB+88 93 29k 11mo
Journal club: orforglipron phase 2 and the non-peptide question
Journal club: orforglipron phase 2 and the non-peptide question Writing it up because I had to work it out twice and would rather nobody else did. Orforglipron phase 2, and specifically the version of it that…
KBLKSSJLB+120 132 13k 1d
Second pass at: Reading a trial's population section before its results
Second pass at: Reading a trial's population section before its results Writing it up because I had to work it out twice and would rather nobody else did. Reading STEP 1 ( N Engl J Med , 2021) for the…
VTNPSCSDAS 4 9.5k 10h
SURMOUNT-4 and what withdrawal data does and does not tell an individual
SURMOUNT-4 and what withdrawal data does and does not tell an individual — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on…
NSLMAADKA 4 42k 11mo